Distinguishing types 1 and 2M von Willebrand disease
暂无分享,去创建一个
[1] E. Favaloro,et al. von Willebrand Disease: Local Diagnosis and Management of a Globally Distributed Bleeding Disorder , 2011, Seminars in thrombosis and hemostasis.
[2] E. Favaloro,et al. Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay , 2010, Journal of thrombosis and haemostasis : JTH.
[3] E. Favaloro,et al. Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease , 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[4] E. Favaloro,et al. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays? , 2009, Thrombosis research.
[5] E. Favaloro. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD): a rebuttal , 2008, Journal of thrombosis and haemostasis : JTH.
[6] E. Favaloro,et al. Lower Limit of Assay Sensitivity: An Under-recognised and Significant Problem in von Willebrand Disease Identification and Classification , 2008, American Society for Clinical Laboratory Science.
[7] J. Goudemand,et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD) , 2008, Journal of thrombosis and haemostasis : JTH.
[8] P. James,et al. Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study , 2007, Journal of thrombosis and haemostasis : JTH.
[9] L. O'Brien,et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. , 2007, Blood.
[10] P. Mannucci,et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor , 2006, Journal of thrombosis and haemostasis : JTH.
[11] A. Street,et al. Reducing errors in identification of von Willebrand disease: the experience of the royal college of pathologists of australasia quality assurance program. , 2006, Seminars in thrombosis and hemostasis.
[12] S. Kitchen,et al. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. , 2006, Seminars in thrombosis and hemostasis.
[13] J. Goudemand,et al. The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor. , 2001, Blood.
[14] F. Martínez,et al. Search for mutations in a segment of the exon 28 of the human von Willebrand factor gene: New mutations, R1315C and R1341W, associated with type 2M and 2B variants , 1998, American journal of hematology.